Abstract
Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. P-glycoprotein is an important and the best-known membrane transporter involved in MDR. Several strategies have been used to address MDR, especially P-glycoprotein-mediated drug resistance in tumors. However, clinical success has been limited, largely due to issues regarding lack of efficacy and/or safety. Nanoparticles have shown the ability to target tumors based on their unique physical and biological properties. To date, nanoparticles have been investigated primarily to address P-glycoprotein and the observed improved anticancer efficacy suggests that nanomedicinal strategies provide a new opportunity to overcome MDR. This article focuses on nanotechnology-based formulations and current nanomedicine approaches to address MDR in tumors and discusses the proposed mechanisms of action.
Original language | English |
---|---|
Pages (from-to) | 597-615 |
Number of pages | 19 |
Journal | Nanomedicine |
Volume | 5 |
Issue number | 4 |
DOIs | |
State | Published - Jun 2010 |
Keywords
- Brij
- Drug delivery
- Efflux transporters
- Lipid formulation
- Nanoparticle
- P-glycoprotein
- Pluronic
- Vitamin e tpgs